Explore the vast range of titles available.

Many studies have suggested that onchocerciasis might be associated with epilepsy. Therefore, we did a cohort study to assess the incidence of epilepsy relative to Onchocerca volvulus skin microfilarial density (MFD) measured during childhood and to assess the possibility of a temporal relationship. During onchocerciasis surveys undertaken in 25 villages in Cameroon during 1991–93, we measured MFD in individuals aged 5 years or older. In 2017, we revisited seven of these villages. With a standardised five-item questionnaire, we collected information on the occurrence of epilepsy in 856 individuals who were aged 5–10 years in 1991–93, and had MFD determined during the original surveys. We did multivariable analyses to assess the overall incidence and incidence ratios taking into account age, sex, individual MFD in 1991–93, and onchocerciasis endemicity level in the village. In 2017, we obtained data on the history of epilepsy for 85% (729 of 856) of individuals. Among these individuals, we classified 60 as being suspected cases of epilepsy. The overall incidence of epilepsy was 350 per 100 000 person-years (95% CI 270–450). The adjusted incidence ratio for developing epilepsy was 7·07 (95% CI 0·98–51·26; p=0·0530) in individuals with initial MFD of one to five microfilariae per skin snip (mf per snip), 11·26 (2·73–46·43) in individuals with six to 20 mf per snip, 12·90 (4·40–37·83) in individuals with 21–50 mf per snip, 20·00 (3·71–108·00) in individuals with 51–100 mf per snip, 22·58 (3·21–158·56) in individuals with 101–200 mf per snip, and 28·50 (95% CI 3·84–211·27; p=0·0010) in individuals with more than 200 mf per snip, compared with that of individuals without detectable densities of skin microfilariae. Individual O volvulus MFD in childhood was associated with the risk of either seizures or epilepsy in an onchocerciasis focus in Cameroon. This temporal relationship suggests a potential causal link between onchocerciasis and epilepsy. European Research Council, NSETHIO Project.

Onchocerciasis elimination currently relies on repeated ivermectin-based preventive chemotherapy. Current World Health Organization's guidelines strongly recommend, though with low evidence of certainty, the use of Ov16 serology testing in children younger than 10 years old to assess whether mass drugs administration can be safely stopped. Therefore, more evidences are needed to support the use of this marker as sero-evaluation tool. This study aimed at determining the relationship between microfilaridermia and anti-Ov16 IgG4, and their variation according to age, gender and ivermectin intake history. A cross-sectional survey was conducted in an area where ivermectin-based MDA has been implemented since more than 20 years. A questionnaire was used to record ivermectin intake history for the last 5 years. All volunteers aged ≥2 years were tested for microfilaridermia. IgG4 antibodies against Ov16 antigen were determined using the Standard Diagnostic Ov16 IgG4 ELISA kits and the recombinant anti-Ov16 AbD19432 antibodies. Prevalences, microfilaridermia counts and IgG4 concentrations were compared with regards to age, gender and history of ivermectin intake. The prevalence of skin microfilariae was 23.4% (95% CI: 23.4-30.8), whereas Ov16 seroprevalence was 53.2% (95% CI: 47.9-58.4). A moderate positive percentage agreement (50.4%) and a high negative percentage agreement (69.2%) was found between skin snip and Ov16 serology in the whole population, while in children aged <10 years, the agreements were higher (positive percentage agreement: 62.6%; negative percentage agreement: 83.5%). In addition, no associations were found between ivermectin intake, Mf counts and estimated IgG4 concentration of participants. Anti-Ov16 IgG4 were higher in individuals harboring microfilariae than their negative counterparts (p<0.0001), though a negative correlation was found between skin microfilarial counts and anti-Ov16 IgG4 levels (r = -0.2400; p = 0.03). No variation in microfilarial counts according to age and gender was observed. Though positively correlated with age (r = 0.4020; p<0.0001), IgG4 was significantly different between the different age classes (p<0.0001). Our results revealed moderate positive and negative agreements between parasitological and immunological parameters of onchocerciasis infection after several rounds MDA. Anti-Ov16 IgG4 levels increased with age but decreased with microfilarial counts, suggesting a variation of anti-Ov16 IgG4 as a result of constant exposure and accumulation of infection. This brings evidence sustaining the use of Ov16 serology in children as evaluation tool. However, additional investigations are needed to further reshape the appropriate age range among children aged <10 years old.

Current knowledge of ocular manifestations of loiasis is limited to the transient subconjunctival passage of the adult filaria and anecdotal reports of posterior segment lesions. Therefore, the ocular burden of loiasis is likely underestimated since it has never been systematically assessed at the population level. We aimed to evaluate the relationship of Loa loa microfilaremia and recent eye worm passage with chronic ocular lesions identified through comprehensive ophthalmological assessment in an endemic area. Subjects aged ≥ 15 years, residing in Akonolinga for ≥ 5 years, without filaricidal treatment for ≥3 years, were screened for filariases. After excluding participants with onchocerciasis lesions, a subset of randomly selected participants was assessed by ophthalmologists blinded to blood test results then allocated to four groups defined by microfilarial load (MFL) on calibrated thick blood film: G1 (Loa MFL = 0), G2 (MFL < 8000/mL), G3 (MFL ≥ 8000/mL), G4 (co-infestation with Mansonella MFL > 100/mL). The ophthalmological assessment comprised distance visual acuity, examination of the anterior segment with a slit lamp, and fundoscopy. The primary analysis consisted of univariable comparisons of the frequency of abnormal findings across four groups (G1 - 4) or two groups defined by history of eye worm passage. The secondary analysis consisted of a multivariable logistic regression analysis of the relationship of high Loa MFL (≥8000/mL) with chorioretinitis and eye worm passage with unilateral ametropia, adjusting for confounders. Of 1511 subjects screened, 200 underwent ophthalmological assessment, including 65, 69, 35, and 16 in G1 to 4. History of eye worm passage in the previous year was reported by 121 participants (65.4%). Unilateral ametropia was more prevalent in people with history of eye worm passage in the previous year (26.5% versus 10.9%, p = 0.014). Chorioretinitis was the most frequent posterior segment lesion (n = 11, 6.1%) and was most prevalent in G3 (14.3%). The frequency of chorioretinitis was higher in participants with moderate-to-severe visual impairment (27.3% versus 4.4%, p = 0.002). High Loa MFL was an independent predictor of chorioretinitis (adjusted OR=5.28; p = 0.01). History of eye worm passage in the previous year was independently associated with unilateral ametropia (adjusted OR=3.27, p = 0.0088). This study has, for the first time, provided evidence of independent association between history of eye worm passage and unilateral ametropia, and between high Loa MFL and severe chorioretinal lesions. This suggests that loiasis should be classified as a neglected tropical disease.

Background Onchocerciasis is a neglected tropical disease with 217.5 million people globally at risk of having the infection. In both settled and semi-nomadic communities of Massangam Health District in Cameroon, Sightsavers has been carrying out test-and-treat with doxycycline and twice-yearly ivermectin distribution. This paper focuses on the cost of test-and-treat with doxycycline in the two community contexts of settled and semi-nomadic. Methods For the valuation, a combination of gross or micro-costing was used to identify cost components, as well as bottom-up and top-down approaches. The opportunity costs of vehicle and equipment use were estimated and included. Not included, however, were the opportunity costs of building use and Ministry of Public Health staff salaries. We only captured the incremental costs of implementing test-and-treat activities as part of a functional annual community-directed treatment with the ivermectin programme. Results We estimate the economic cost per person tested and cost per person treated in Massangam to be US$135 and US$667 respectively. Total implementation cost in the settled community was US$79,409, and in the semi-nomadic community US$69,957. Overall, the total economic cost of implementing the doxycycline test-and-treat strategy for onchocerciasis elimination in Massangam came to US$168,345. Financial costs represented 91% of total costs. Conclusions Unit costs of test-and-treat in both settled and semi-nomadic communities are higher than unit costs of community-directed treatment with ivermectin. However, it is critical to note that a two-year implementation shows a significantly larger reduction in infection prevalence than the preceding 20 years of annual community-directed treatment with ivermectin. Test-and-treat with doxycycline may be a cost-effective intervention in places where the prevalence of microfilaria is still high, or in hard-to-reach areas where community-directed treatment with ivermectin and MDA coverage are not high enough to stop transmission or where marginalised populations consistently miss treatment.

Background Ghana has adopted and implemented intermittent preventive treatment using sulfadoxine-pyrimethamine (IPTp-SP) and insecticide-treated nets (ITNs) in an antenatal care (ANC) context to prevent malaria among pregnant women. However, the increased ANC attendance and its frequency facilitated by a free maternal health care policy in Ghana does not correspond with the uptake of IPTp-SP and ITN use among pregnant women. This study sought to elucidate the contextual health system factors influencing the delivery of IPTp-SP and ITN from a related quantitative study conducted in Ghana. Methods This is the qualitative section of a mixed-methods study design, where audio recorded key informant interviews (KIIs) were conducted with health workers from across health facilities, districts, regional and national health directorates. The KIIs elicited information on health worker knowledge, perceptions, and rationale for the delivery practices of IPTp-SP and ITN revealed in the quantitative findings. The interviews were transcribed and imported into NVivo for analysis. Using the World Health Organization (WHO) Health Systems Framework as the theoretical basis, thematic analysis was conducted under broad themes of the building blocks. Findings are presented in narrative quotes, with a mindmap used to summarize the various health system factors and their interrelated relationship influencing the delivery of IPTp-SP and ITN. Results Health system factors identified included health staff untrained on malaria delivery directives due to an ineffective trainer of trainer (ToT) system. Additionally, health worker confusion on when to commence SP (at quickening or ≥ 16 weeks) was found to result in delayed start of SP. Stock-outs in facilities due to procurement delays at the national level resulted in missed opportunities to deliver SP to eligible pregnant women at the ANC. Similarly, ITN stock outs led to eligible pregnant women not receiving one at ANC clinics. Conclusion Poor health worker knowledge on policy directives, a consequence of ineffective training strategy led to delayed delivery of IPTp-SP to eligible pregnant women. Supply chain management challenges related to stock of SP and ITN resulted in missed opportunities to deliver the interventions to pregnant women attending ANC.

The effectiveness of the “Slash and Clear” method in reducing blackfly populations in low transmission areas is established, but its impact in high transmission settings with large rivers and dense vectors is yet to be proven. A community-based intervention study was conducted in the Mbam Valley, Centre Cameroon, involving two sites: Bayomen (control) and Biatsota (intervention). In each arm, baseline blackfly densities were collected over one year using the human landing method. The intervention consisted of destroying the trailing vegetation where blackflies breed. Blackfly densities were collected post-intervention to assess the impact of the intervention. Post-intervention data showed a 50.8% reduction in blackfly density in Biatsota (mean number of collected blackflies from 1936 to 953), while a reduction of 26.7% was observed in Bayomen (mean number of collected blackflies from 2418 to 1774). The reduction rate attributable to the intervention was 32.9%. Statistical analysis confirmed that the reduction in blackfly density was significantly greater in the intervention site. This study demonstrates the feasibility and significant impact of the “Slash and Clear” method in high transmission areas. However, further research is required to assess its long-term effects and determine how this strategy can be scaled up and sustained until onchocerciasis elimination is achieved.

Albendazole is an orally administered anti-parasitic medication with widespread usage in a variety of both programmatic and clinical contexts. Previous work has shown that the drug's pharmacologically active metabolite, albendazole sulfoxide, is characterised by substantial inter-individual pharmacokinetic variation. This variation might have implications for the efficacy of albendazole treatment, but current understanding of the factors associated with this variation remains incomplete. We carried out a systematic review to identify references containing temporally disaggregated data on the plasma concentration of albendazole and/or (its pharmacologically-active metabolite) albendazole sulfoxide following a single oral dose. These data were then integrated into a mathematical modelling framework to infer albendazole sulfoxide pharmacokinetic parameters and relate them to characteristics of the groups being treated. These characteristics included age, weight, sex, dosage, infection status, and whether patients had received a fatty meal prior to treatment or other drugs alongside albendazole. Our results highlight a number of factors systematically associated with albendazole sulfoxide pharmacokinetic variation including age, existing parasitic infection and receipt of a fatty meal. Age was significantly associated with variation in albendazole sulfoxide systemic availability and peak plasma concentration achieved; as well as the clearance rate (related to the half-life) after adjusting for variation in dosage due to differences in body weight between children and adults. Receipt of a fatty meal prior to treatment was associated with increased albendazole sulfoxide systemic availability (and by extension, peak plasma concentration and total albendazole sulfoxide exposure following the dose). Parasitic infection (particularly echinococcosis) was associated with altered pharmacokinetic parameters, with infected populations displaying distinct characteristics to uninfected ones. These results highlight the extensive inter-individual variation that characterises albendazole sulfoxide pharmacokinetics and provide insight into some of the factors associated with this variation.

Introduction Malaria interventions including use of Sulfadoxine-Pyrimethamine as Intermittent Preventive Treatment (IPTp-SP) and distribution of Insecticide Treated Nets (ITNs) have been implemented through ante-natal clinic (ANC) services in Ghana. Yet, the high ANC attendance is not commensurate with the uptake of these interventions, with missed opportunities to deliver the interventions. This study sought to assess the health system factors affecting access and delivery of IPTp-SP and ITN as defined by the Ghana Malaria Policy Guideline to eligible pregnant women attending ANC clinic sessions. Methods A quantitative cross-sectional study was conducted in the Volta Region of Ghana, with data collected across three levels of health care delivery facilities, including hospitals, health centres and Community-Based Health Planning Service (CHPS) compounds. Data collection included structured observation checklists to document the communication and interaction between the ANC health staff and pregnant women. Additionally, structured questionnaires were used to elicit information on cadre, trainings attended, knowledge and delivery practices of health workers on IPTp-SP and ITN. Stata 16 was used for data analysis, and a defined delivery algorithm was used to compute appropriate and inappropriate delivery practices, using the Ghana policy directive as a guide. Predictors of appropriate delivery were determined using logistic regression analysis. Results Approximately 97% of the 680 ANC observations had complete information for analysis. Of these, 78% (511/657) were eligible for IPTp-SP after excluding women who have less than 16 weeks of gestation, G6PD deficient, malaria positive and have taken 5 doses of IPTp-SP prior to day of observation. Appropriate delivery of IPTp-SP was 76% (390/511). Despite the availability of SP, 15% (75/511) of all eligible women were not offered the medication and 37% (44/119) of inappropriate delivery was recorded during periods of stock out. ITNs were appropriately delivered to 59% (139) out of 237 eligible women. Thirty-two percent (77/237) of eligible women, mostly continuing ANC clients, were not given ITN despite stock availability. Conclusions IPTp-SP was appropriately delivered to most of the eligible pregnant women compared to ITN. While stock out of both intervention could account for inappropriate delivery, despite stock availability, IPTp-SP and ITN were not delivered to some eligible women.

After the closure of the African Programme for Onchocerciasis Control (APOC) in 2015, the Ministry of Public Health of Cameroon has continued implementing annual community-directed treatment with ivermectin (CDTI) in endemic areas. The World Health Organization has proposed that 12 countries be verified for elimination (interruption) of transmission by 2030. Using Rapid Epidemiological Mapping of Onchocerciasis, a baseline geostatistical map of nodule (onchocercoma) prevalence had been generated for APOC countries, indicating high initial endemicity in most regions of Cameroon. After more than two decades of CDTI, infection prevalence remains high in some areas. This study aimed at mapping the spatio-temporal evolution of Onchocerca volvulus prevalence from 1971 to 2020 to: i) identify such areas; ii) indicate where alternative and complementary interventions are most needed to accelerate elimination, and iii) improve the projections of transmission models. A total of 1,404 georeferenced (village-level) prevalence surveys were obtained from published articles; the Expanded Special Project for Elimination of Neglected Tropical Diseases portal for Cameroon; independent researchers and grey literature. These data were used together with bioclimatic layers to generate model-based geostatistical (MBG) maps of microfilarial prevalence for 1971-2000; 2001-2010 and 2011-2020. Time-period was negatively and statistically significantly associated with prevalence. In 1971-2000 and 2001-2010, prevalence levels were high in most regions and ≥60% in some areas. Mean predicted prevalence declined in 2011-2020, reaching <20% in most areas, but data for this period were sparse, leading to substantial uncertainty. Hotspots were identified in South West, Littoral and Centre regions. Our results are broadly consistent with recent MBG studies and can be used to intensify onchocerciasis control and elimination efforts in areas with persisting transmission, providing spatio-temporal prevalence trends to which transmission models can be fitted to improve projections of onchocerciasis elimination by 2030 and beyond.

Loiasis was long deemed to be a benign condition, but individuals with high Loa loa microfilarial densities (MFD) are at risk of serious adverse events (SAEs) including encephalopathy following ivermectin (IVM) administration. The risk of marked AE or SAE is usually considered when MFD exceeds 8000 microfilariae (mf)/mL or 30,000 mf/mL, respectively. There are no international guidelines on the treatment of loiasis, resulting in a variety of practices worldwide for the treatment of infected individuals outside endemic areas. Our objective was to determine the probabilities of SAEs after IVM administration at the usual thresholds, and to refine those thresholds using individual characteristics such as age and sex. We used data from two clinical trials conducted in Cameroon where L. loa MFD were determined before IVM administration. The risk of SAE was modeled as a logistic function of age, sex, and MFD transformed as a first-order fractional polynomial. SAEs probabilities were found to be <104 for MFD<2000 mf/mL, > 1‰ for MFD >8000 mf/mL, >1% for MFD>20,000 mf/mL, and >2.5% for MFD>30,000 mf/mL. We showed that specific categories may be at a higher risk of SAE than expected. Specifically, in order not to exceed 1% risk, the corresponding thresholds would be 18,000 mf/mL for females in the 31-40 age group; 16,000 mf/mL for males in the 21-30 age group; 12,000 mf/mL for males in the 31-40 age group; and 19,000 mf/mL for males in the 41-50 age group. Our study suggests that IVM should be used with caution for males or individuals in specific age categories with a high L. loa MFD. For these high risk groups, lowering the thresholds to 8000 mf/mL should be considered. The increased risk in males requires further investigation to understand the pathophysiological phenomena involved that are crucial to prevent and manage SAEs.